Related Experiment Video
Updated: Sep 9, 2025
04:24
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
11.7K
Smartphone application-based interventions for cardiometabolic risk factor management: A systematic review and
Makiko Abe1, Tetsuo Hirata2, Natsumi Morito2,3
1Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. mabe@fukuoka-u.ac.jp.
Summary
Smartphone apps significantly reduce cardiometabolic risk factors like glucose, BMI, and LDL cholesterol. These health benefits diminish by 12 months, highlighting the need for sustained interventions.
Area of Science:
- Cardiovascular Health
- Metabolic Health
- Digital Health Interventions
Background:
- Previous research established smartphone application-based interventions' impact on blood pressure.
- This study extends prior work by analyzing effects on broader cardiometabolic risk factors.
Purpose of the Study:
- To conduct a secondary analysis of smartphone application-based interventions' effects on cardiometabolic risk factors.
- To evaluate changes in fasting plasma glucose, BMI, waist circumference, body weight, and lipid profiles.
Main Methods:
- Systematic search of MEDLINE, Cochrane Library, and Ichushi for relevant randomized controlled trials and observational studies.
- Random-effects models were employed to pool mean changes and 95% confidence intervals (CIs).
- Included 76 studies with 46,459 participants, comparing app-based interventions to usual care.
Main Results:
- Significant reductions observed at 6 months in fasting plasma glucose, BMI, waist circumference, body weight, LDL cholesterol, total cholesterol, and triglycerides.
- Effects on these markers diminished by 12 months, with BMI reduction showing interaction with follow-up duration.
- No significant differences in blood pressure reduction across baseline levels; greater LDL cholesterol reduction noted in East Asians.
Conclusions:
- Smartphone application-based interventions show potential for improving cardiometabolic health and supporting self-management.
- Sustained intervention effects may be necessary, as benefits gradually declined by 12 months.
- Intervention effectiveness may vary across different populations, as suggested by ethnic differences in LDL cholesterol reduction.
Related Concept Videos
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:15Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
01:30Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
01:28Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37